

ARTICLE

Received 11 May 2014 | Accepted 30 Sep 2014 | Published 5 Nov 2014

DOI: 10.1038/ncomms6425

An epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth

Xuanming Shi¹, Zilai Zhang¹, Xiaoming Zhan¹, Mou Cao¹, Takashi Satoh², Shizuo Akira², Karl Shpargel³, Terry Magnuson³, Qingtian Li⁴, Rongfu Wang⁴, Chaochen Wang⁵, Kai Ge⁵ & Jiang Wu¹

The Sonic hedgehog (Shh) signalling pathway plays important roles during development and in cancer. Here we report a Shh-induced epigenetic switch that cooperates with Gli to control transcription outcomes. Before induction, poised Shh target genes are marked by a bivalent chromatin domain containing a repressive histone H3K27me3 mark and an active H3K4me3 mark. Shh activation induces a local switch of epigenetic cofactors from the H3K27 methyltransferase polycomb repressive complex 2 (PRC2) to an H3K27me3 demethylase Jmjd3/Kdm6b-centred coactivator complex. We also find that non-enzymatic activities of Jmjd3 are important and that Jmjd3 recruits the Set1/MLL H3K4 methyltransferase complexes in a Shh-dependent manner to resolve the bivalent domain. *In vivo*, changes of the bivalent domain accompanied Shh-activated cerebellar progenitor proliferation. Overall, our results reveal a regulatory mechanism that underlies the activation of Shh target genes and provides insight into the causes of various diseases and cancers exhibiting altered Shh signalling.

¹Department of Physiology and Developmental Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. ²Laboratory of Host Defense, World Premier Institute Immunology Frontier Research Center and Department of Host Defense, RIMD, Osaka University, Osaka, Japan.

³Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA. ⁴Center for Inflammation and Epigenetics, The Methodist Hospital Research Institute, Houston, Texas 77030, USA. ⁵NIDDK, NIH, Bethesda, Maryland 20892, USA. Correspondence and requests for materials should be addressed to J.W. (email: jiang9.wu@utsouthwestern.edu).

Sonic hedgehog (Shh) signalling, mediated by Patched and Smoothened, functions as a morphogen or a mitogen during many developmental processes^{1–3}. Mutations in the Shh pathway components lead to developmental diseases and cancers^{4,5}. Shh signalling produces specific transcriptional outcomes by differentially regulating the activities of Gli family transcription factors^{1,2}. Under basal conditions, Gli3, and to a lesser extent Gli2, is processed to generate a truncated Gli repressor (GliR) that represses basal expression of Shh target genes. Shh signalling de-represses and activates target genes by inhibiting Gli3 processing, inducing Gli3 degradation and activating Gli2/Gli1 transcription activators (GliA). The morphogen activity of Shh (for example, in neural tube patterning) is largely dependent on its role as an antagonist of GliR function. GliA-mediated transcription activation in response to Shh is critical for neural tube progenitor specification in the most ventral areas^{6,7}. The mitogenic effects of Shh in many normal and cancer cell types also require the GliA activities^{1,2}. For example, Shh/GliA signalling plays a predominant role in the proliferation of early postnatal cerebellum granule neuron precursors (CGNPs)^{8–11}. Mutations that result in constitutively active Shh signalling cause CGNP overproliferation and are the leading genetic causes of the childhood brain tumour medulloblastoma^{4,5}. Recent studies suggest a link between active Shh pathways and other cancers, and it appears that the oncogenic functions of the Shh pathway require GliA-mediated transcription activation^{1,4}.

Despite extensive studies of Hedgehog signalling in multiple organisms, one fundamental question remains to be answered: how do Gli proteins de-repress and activate target gene expression in response to Shh? Epigenetic factors play critical roles in determining transcription outcomes by regulating chromatin structures and accessibilities of DNA to transcription machineries. Recently, we identified a Brg1-containing chromatin remodelling complex that represses basal expression and activates Shh signalling-induced target gene expression¹². Interestingly, our results suggest that Brg1 mainly functions as a docking site for other chromatin regulators. Brg1 deletion leads to changes in histone modifications in the regulatory regions of Shh target genes. Thus, additional histone modifiers may regulate Shh signalling, and it is likely that Shh signalling-induced transcription factor exchange from GliR to GliA is accompanied by changes of associated epigenetic cofactor complexes to produce specific chromatin environments and transcription outcomes.

Bivalent chromatin domains containing both a repressive H3K27me3 and an active H3K4me3 mark are found in the regulatory regions of many developmental genes in stem cells; these bivalent domains keep gene expression repressed but poised for induction^{13–16}. During development, the resolution of the bivalent domain accompanies the activation or silencing of the poised genes. The PRC2 complex catalyses the addition of H3K27me3 ref. 17, whereas the H3K27me3-specific demethylases UTX/Kdm6a and Jmjd3/Kdm6b remove it^{18–22}. UTX is also a subunit of H3K4 methyltransferase MLL2/3 complexes^{20,23}, which may coordinately activate bivalent genes by removing H3K27me3 and increasing levels of H3K4me3. The Jmjd3 catalytic domain shares homology with UTX; however, genetic analyses indicate that they play distinct roles during development^{24–27}. Although Jmjd3 does not appear to be a subunit of Set1/MLL complexes, it is able to interact with Set1/MLL complexes²¹. The interaction is not strong, and it is not clear whether this interaction plays a role in resolving bivalent domains during bivalent gene activation. How bivalent domains are regulated coordinately by epigenetic factors in response to specific developing signals has not been well understood.

In this study, we identified a bivalent domain at the regulatory regions of poised Shh target genes. Shh signalling induces an epigenetic switch to resolve bivalent domains and activates gene expression. PRC2 complexes repress Shh target genes by maintaining the repressive H3K27me3 levels, whereas Shh-induced recruitment of Jmjd3 activates target genes by displacing PRC2, enzymatically removing H3K27me3 and recruiting Set1/MLL complex. The central role of Jmjd3 in regulating Shh-activated gene expression was demonstrated *in vivo* in Shh activation-dependent development and medulloblastoma growth. Our study reveals an important epigenetic mechanism underlying the gene activation in response to Shh and identifies a potential target to disrupt the mitogenic effect of Shh signalling during tumour progression.

Results

Poised Shh-responsive genes are marked by a bivalent domain.

To understand the chromatin environment of poised Shh target genes, we analysed the publicly available histone modification data obtained from Shh-responsive mouse embryonic fibroblast (MEF) cells (Geo data sets GSE21271 (ref. 28)). MEFs as well as NIH3T3 mouse fibroblasts express both Gli repressors and activators and are widely used in studies of Shh signalling²⁹. Several universal Gli target genes, such as *Gli1*, *Ptch1* and *Hhip*, are relatively restricted to the Shh pathway, and their expression reflects Shh/Gli signalling activities. In this screen, we identified an H3K27me3/H3K4me3 bivalent domain in the regulatory regions of these Shh target genes (Fig. 1a). The H3K27me3 marks are close to the previously identified Gli-binding regions^{30,31}. These regions are close to the promoters and may represent proximal enhancers. In contrast, the Shh-independent *Gli3* gene was only marked with H3K4me3, whereas a silenced neural-specific target gene *Olig2* was only marked with H3K27me3 (Fig. 1a). We performed an RNA-seq analysis to compare expression profiles in wild-type MEFs cultured with or without Shh; expression of 25 genes was significantly induced by Shh treatment ($P < 0.05$). Eighteen of these contain the bivalent chromatin domain (Supplementary Table 1). Other typical repressive marks, such as H3K9me3 and the PRC1-mediated ubiquitinated H2AK119 (refs 32,33), were not present. Thus, the poised Shh target genes may be specifically marked by the bivalent chromatin domain.

Using *Gli1* as a representative Shh target gene, we examined whether the marks in the bivalent domain changed with Shh induction. Using chromatin immunoprecipitation (ChIP), we found that H3K27me3 was present in the regulatory region of *Gli1* gene, and levels were significantly reduced on Shh treatment (Fig. 1b). H3K4me3 levels in the *Gli1* promoter were significantly increased in Shh-treated MEFs (Fig. 1b). Similar changes were observed when *Gli1* and other Shh target genes were de-repressed in *Gli3*^{−/−} MEFs or further activated in Shh-treated *Gli3*^{−/−} MEFs (Supplementary Figs 1 and 2). Thus, Gli-mediated Shh target gene de-repression and activation are accompanied with the removal of H3K27me3 and increase in levels of H3K4me3.

PRC2 and Jmjd3 are important for Shh target gene expression.

To determine whether H3K27me3 reduction is a causal factor in the Shh-mediated gene activation, we manipulated the enzymes that add or erase H3K27me3 marks. The PRC2 complex, which methylates H3K27, contains three essential subunits, EZH2, SUZ12 and EED¹³. RNAi inhibition of *SUZ12* expression led to decreased local H3K27me3 levels and increased *Gli1* basal expression (Fig. 1c). In *EZH2*^{−/−} MEFs^{34,35}, global H3K27me3 levels were decreased and basal expression of Shh target genes such as *Gli1* and *Ptch1* was increased compared with those in




Figure 1 | PRC2 and Jmjd3 regulate Shh target gene expression by modulating the bivalent domains. (a) Analyses of ChIP-seq data (Geo datasets GSE21271) showed bivalent domains close to transcription start sites of Shh target genes in MEFs. Red and green bars represent the chromatin regions enriched for H3K27me3 and H3K4me3, respectively. The 5' regions of the genes are shown as blue lines. *Gli3* is not a Shh target gene; *Olig2* is a neural-specific Shh target gene not expressed in MEFs. (b) Activation of *Gli1* by addition of Shh to MEF cultures was associated with decreased H3K27me3 and increased H3K4me3 levels in the *Gli1* regulatory region. The mRNA levels were measured by RT-qPCR, and the ChIP results were analysed by ChIP-qPCR. Histone H3 and IgG ChIP were used as histone and antibody controls, respectively (means \pm s.d., $n = 3$). (c) Reducing SUZ12 levels in MEFs by shRNA treatment led to decreased local H3K27me3 levels and increased *Gli1* expression as shown by RT-qPCR. Histone H3 ChIP was used for ChIP normalization (means \pm s.d., $n = 3$). (d) Deletion of *EZH2* led to increased basal expression of *Gli1* and *Ptch1*, but not *Gli2/3*, as shown by RT-qPCR (means \pm s.d., $n = 3$). (e) Upper panel: exogenous wild-type EZH2, but not the F667I mutant, rescued *Gli1* expression defects in *EZH2*^{-/-} MEFs as analysed by RT-qPCR. Lower panel: western blots show the expression of EZH2 and global H3K27me3 in wild-type and *EZH2*^{-/-} MEFs (means \pm s.d., $n = 3$). (f) Wild-type and *Jmjd3*^{-/-} MEFs were treated with Shh. RT-qPCR analyses of *Gli1*, *Ptch1* and other Shh-responsive genes are shown (means \pm s.d., $n = 3$). (g) *Jmjd3* deletion led to higher H3K27me3 levels in the *Gli1* regulatory region in Shh-treated MEFs as shown by ChIP-qPCR. A region upstream of *Gli1* and the *CD4* gene were negative controls. Significance was determined using *t*-test or ANOVA with *post hoc t*-test (means \pm s.d., $n = 3$). ** indicates $P < 0.01$ and * indicates $P < 0.05$.

wild-type cells (Fig. 1d). Neither *Gli2* nor *Gli3* expression was affected and *Olig2* was not de-repressed by *EZH2* deletion (Fig. 1d). Only the wild type but not an enzymatically inactive mutant EZH2 (F667I)³⁵ rescued the *Gli1* expression defect (Fig. 1e). These experiments suggest that the PRC2 complex

represses basal Shh target gene expression by maintaining the H3K27me3 mark. This mechanism also provides a possible explanation for the recent findings that *EZH2* deletion leads to a de-repression of Shh target genes in developing limbs and dorsal hindbrains^{36,37}.

In MEFs lacking Jmjd3 ref. 25, an H3K27me3 demethylase, we observed defects in Shh-induced gene activation. The activation of several bivalent Shh-responsive genes identified in RNA-seq experiments (Supplementary Table 1) was significantly impaired in *Jmjd3*^{-/-} MEFs (Fig. 1f). *Jmjd3* deletion resulted in higher local H3K27me3 levels in the *Gli1* gene in the presence of Shh (Fig. 1g) but not in higher global H3K27me3 levels (Supplementary Fig. 3), suggesting that Jmjd3 plays a specific role in Shh target gene activation. RNAi inhibition of *Jmjd3* expression in MEFs phenocopied the *Jmjd3*^{-/-} defects in Shh-induced *Gli1* expression and local H3K27me3 reduction (Supplementary Fig. 4). Notably, lack of another H3K27me3 demethylase, UTX²⁷, did not produce significant effects on Shh-induced target gene expression in MEFs (Supplementary Fig. 5). These results indicate that H3K27me3 and PRC2 are required for the repression of Shh target gene basal expression and that erasure of the mark by Jmjd3 in response to Shh is required for gene activation.

Shh induces a local epigenetic switch from PRC2 to Jmjd3. We next monitored the dynamic binding of PRC2 and Jmjd3 in response to Shh signalling. In the *Gli1* gene, a cluster of Gli-binding sites^{30,31} overlaps the H3K27me3-enriched region (Supplementary Fig. 6A). Using ChIP, we demonstrated that endogenous SUZ12 and, by inference, PRC2, binds to *Gli1*; binding decreased on Shh treatment (Fig. 2a). Conversely, ChIP with a Jmjd3 antibody indicated increased binding of Jmjd3 to the *Gli1* regulatory region on Shh induction (Fig. 2b). A ChIP experiment performed in NIH3T3 cells expressing FLAG-tagged

Jmjd3 or HA-tagged EZH2 confirmed the binding dynamics: Shh treatment reduced EZH2 binding and increased Jmjd3 binding to *Gli1* (Supplementary Fig. S6). In MEFs, levels of EZH2, SUZ12 and Jmjd3 were similar with or without Shh treatment (Fig. 2c,d). Thus, the Shh-induced switch from PRC2 to Jmjd3 in these regulatory regions was not due to changes in the global levels of these factors but was likely caused by an active recruitment of Jmjd3 to replace PRC2 on Shh stimulation. Indeed, in the absence of Jmjd3, a significant amount of SUZ12 remained bound to *Gli1* in Shh-treated cells (Fig. 2a), suggesting that Jmjd3 is required for removal of PRC2 from Shh target genes.

Shh-induced *Gli1/2* activation and binding to target genes may mediate Jmjd3 recruitment. *Gli2* and Shh-induced *Gli1* both can co-immunoprecipitate with Jmjd3 (Fig. 2e,f, Supplementary Fig. 7). The exogenous tagged Jmjd3 proteins are expressed in NIH3T3 cells at relatively low levels, as it is difficult to detect the full-length Jmjd3 proteins with standard western blot. Importantly, RNAi inhibition of *Gli1/2* in Shh-treated MEF cultures (Fig. 2g) reduced Jmjd3 binding to the *Gli1* regulatory region (Fig. 2h) and increased local H3K27me3 levels (Fig. 2i), suggesting that *Gli1/2* are required for Jmjd3 binding to Shh target genes. In contrast, *Gli1/2* binding to Shh target genes was not affected by *Jmjd3* deletion (Supplementary Fig. 8). Thus, *Gli1/2* activators are required for the recruitment of Jmjd3 and possibly other coactivators to displace PRC2 and activate target gene expression. To further confirm that Jmjd3 directly regulates Gli-mediated transcription, we expressed HA-*Gli1* in MEFs and observed that the activation of endogenous Gli target genes by HA-*Gli1* was significantly impaired in *Jmjd3*^{-/-} MEFs compared with that in wild-type cells (Fig. 2j).




Figure 2 | Shh induces a Gli-dependent local epigenetic switch from PRC2 to Jmjd3. (a) ChIP-qPCR indicates the dynamic binding of endogenous SUZ12 to the *Gli1* regulatory region in wild-type and *Jmjd3*^{-/-} MEF cells on Shh induction. (means \pm s.d., $n = 3$). (b) Increased Jmjd3 binding to *Gli1* gene on Shh treatment was shown by ChIP-qPCR (means \pm s.d., $n = 3$). (c) Shh treatment did not reduce levels of PRC2 subunits as shown by EZH2 and SUZ12 western blot. (d) *Jmjd3* expression level was not significantly changed in MEFs by Shh treatment as analysed by RT-qPCR (means \pm s.d., $n = 3$). (e) Jmjd3 co-immunoprecipitates with Gli2. Lysates of NIH3T3 cells transiently transfected with plasmids expressing HA-Jmjd3 and Myc-Gli2 were immunoprecipitated with anti-HA antibodies and blotted with antibodies against HA and Myc. (f) Jmjd3 co-immunoprecipitates with endogenous Gli1. Cell lysates of Shh-treated NIH3T3 cells expressing HA-Jmjd3 were immunoprecipitated with anti-HA antibodies and blotted with antibodies against HA and Gli1. (g) RNAi-induced inhibition of *Gli1* and *Gli2* in Shh-treated MEFs led to (h) decreased Jmjd3 binding and (i) increased H3K27me3 levels in the *Gli1* regulatory region (means \pm s.d., $n = 3$). (j) Deletion of *Jmjd3* in MEFs led to impaired endogenous Shh target gene (*Gli1*, *Ptch1*, *Hhip*) expression induced by lentiviral expressed HA-Gli1 as shown by RT-qPCR. Expressions of endogenous *Gli1* and exogenous HA-Gli1 were measured using primers specific for the 5'-UTR and the HA tag region, respectively. Significance was determined using *t*-test or ANOVA with *post hoc t*-test (means \pm s.d., $n = 3$). ** indicates $P < 0.01$ and * indicates $P < 0.05$.

Shh-induced switch is essential for target gene expression. To determine whether the Shh-induced, Gli-mediated PRC2 to Jmjd3 switch is required for proper target gene expression, we manipulated local PRC2 and Jmjd3 levels to perturb the epigenetic switch, either by increasing local PRC2 levels after Shh treatment or introducing Jmjd3 onto the *Gli1* gene before Shh stimulation. All three Gli proteins contain five conserved zinc-fingers that are sufficient to bind specifically to the Gli consensus sequence³⁸. We fused the Gli3 DNA binding domain (GliDBD) to HA-tagged EZH2 and expressed this fusion in either NIH3T3 cells or MEF cells (Fig. 3a, Supplementary Fig. 9A). GliDBD-EZH2 interacted with endogenous SUZ12 as the two proteins were co-immunoprecipitated (Fig. 3b), suggesting that these proteins form a functional PRC2 complex. In the presence of Shh, GliDBD-EZH2 can bind *Gli1* and increase local H3K27me3 levels as shown by ChIP (Fig. 3c,d, Supplementary Fig. 9B,C). Both GliDBD-EZH2 and exogenous EZH2 reduced Shh-activated *Gli1* expression (Fig. 3e, Supplementary Fig. 9D). GliDBD-EZH2 repressed *Gli1* more effectively and specifically than EZH2; EZH2 also repressed another Shh-independent target gene *HoxA10* (Fig. 3e, Supplementary Fig. 9D). Thus, increasing the local PRC2 concentration in Shh-stimulated conditions effectively repressed *Gli1* expression, indicating that PRC2 must be removed to activate gene expression. Using similar approaches, we found that

GliDBD-Jmjd3 expressed in NIH3T3 cells (Fig. 3f) bound to the Shh target gene regulatory regions under basal conditions (Fig. 3g) and decreased local H3K27me3 (Fig. 3h). GliDBD-Jmjd3 activated Shh target genes even in the absence of Shh stimulation (Fig. 3i). Thus, recruitment of Jmjd3 is sufficient to increase Gli target gene expression before Shh stimulation. These data indicate that the presence of PRC2 represses the expression of Shh target genes, whereas the removal of PRC2 and the recruitment of Jmjd3 on Shh stimulation activate gene expression. Thus, the Shh-induced epigenetic switch from PRC2 to Jmjd3 is essential for target gene activation.

Coordinated target gene activation by Jmjd3 and Set1/MLL.

Our results indicate that Jmjd3 is required for the removal of H3K27me3 and activation of Shh target genes. It is not clear whether its demethylase activity is essential and/or sufficient for this function. The C-terminal fragment of Jmjd3, encompassing the JmjdC domain, is sufficient to catalyse H3K27me3 demethylation and rescues several Jmjd3-deficient phenotypes^{21,25}. The expression of the C-terminal fragment (aa 1,141–1,641) fused with GliDBD (GliDBD-JmjdC) was sufficient to reduce local H3K27me3 levels at *Gli1* locus (Fig. 3g,h), but it did not activate Shh target gene basal expression (Fig. 3i). Thus, the Jmjd3




Figure 3 | The Shh-induced local PRC2 to Jmjd3 switch is essential for proper target gene expression. (a) Total EZH2 levels in NIH3T3 cells expressing the indicated exogenous proteins as shown by western blot with anti-EZH2 antibodies. (b) Exogenous EZH2 and GliDBD-EZH2, but not GliDBD, expressed in NIH3T3 cells interact with endogenous SUZ12 as indicated by IP with an HA antibody and western blot with SUZ12 antibody. All exogenous proteins contain an HA tag. (c) GliDBD-EZH2 proteins are recruited to *Gli1* regulatory region as indicated by ChIP-qPCR with anti-HA antibodies (means \pm s.d., $n = 3$). (d) Local H3K27me3 levels at *Gli1* regulatory region as measured by ChIP-qPCR in Shh-treated NIH3T3 cells expressing exogenous proteins (means \pm s.d., $n = 3$). (e) RT-qPCR analyses of *Gli1* and *HoxA10* in Shh-treated NIH3T3 cells expressing the indicated exogenous proteins (means \pm s.d., $n = 3$). (f) Expression of fused Jmjd3 proteins in transfected NIH3T3 cells detected by western blot using anti-HA antibodies. The full-length GliDBD-Jmjd3 protein band is marked with a star. (g) Binding of HA-tagged GliDBD fusion Jmjd3 proteins and (h) local H3K27me3 levels at *Gli1* and *Ptch1* loci as shown by ChIP-qPCR. Histone H3 ChIP was used for normalization (means \pm s.d., $n = 3$). (i) RT-qPCR analyses of *Gli1*, *Ptch1* and *HoxA10* in NIH3T3 cells expressing the indicated exogenous Jmjd3 proteins in basal conditions (means \pm s.d., $n = 3$). Significance was determined using *t*-test or ANOVA with *post hoc t*-test; ** indicates $P < 0.01$ and * indicates $P < 0.05$. The comparisons are all against the control samples.

enzymatic activity alone is not sufficient to activate Shh target genes. We performed rescue experiments in NIH3T3 cells co-expressing an shRNA targeting *Jmjd3* and exogenous RNAi-resistant genes encoding *Jmjd3*, the JmjC domain, or the *Jmjd3*-H1388A enzymatically inactive proteins²¹. The cultures were co-transfected with plasmids expressing GFP-Gli1 to activate the endogenous Shh target genes (Fig. 4a,b). Although each of these *Jmjd3* proteins bound to the *Gli1* regulatory region (Fig. 4c), only wild-type full-length *Jmjd3* rescued the defective Gli1-induced gene expression in *Jmjd3*-knockdown cells (Fig. 4a), indicating that the demethylase activity is necessary but not sufficient for activation of Gli target genes. The non-enzymatic activity of *Jmjd3* may serve to recruit other epigenetic regulators.

Activation of bivalent genes is accompanied by coordinated changes in levels of both H3K27me3 and H3K4me3. Thus, it is likely that *Jmjd3* and the Set1/MLL family of H3K4me3 methyltransferase complexes function cooperatively to regulate Shh-induced gene activation. Ash2L, RbBP5, DPY30 and WDR5 are essential subunits for all Set1/MLL family complexes³⁹. RNAi inhibition of expression of individual subunits significantly impaired *Gli1* expression in Shh-treated NIH3T3 cells (Fig. 4d). To determine whether Shh signalling regulates Set1/MLL complex binding to Shh target genes, we performed ChIP with WDR5 antibodies. Consistent with the Shh-induced increase of local H3K4me3, the binding of endogenous WDR5 to *Gli1* and *Ptch1* regulatory regions was significantly increased on Shh treatment (Fig. 4e). Importantly, in cells deficient in *Jmjd3*, Shh-induced WDR5 binding to target genes and local H3K4me3 increases were significantly impaired (Fig. 4e). Consistent with this result, local levels of H3K4me3 in the *Gli1* gene in the presence of Shh were significantly lower in *Jmjd3*^{-/-} MEFs than in wild-type cells (Supplementary Fig. 10). Thus, *Jmjd3* is required for Set1/MLL complexes recruitment to target genes in response to Shh stimulation.

It is not clear whether the interaction between *Jmjd3* and Set1/MLL complexes²¹ plays a role in resolving bivalent domains; however, our co-immunoprecipitation analyses showed that interactions between *Jmjd3* and Set1/MLL subunits, WDR5 and ASH2L, were significantly enhanced by Shh stimulation (Fig. 4f, Supplementary Fig. 11). The Shh-induced *Jmjd3*-MLL interaction is potentially phosphorylation-dependent, as treating the lysate with λ -phosphatase reduced the interaction to the basal level (Supplementary Fig. 11). This result suggests that Shh signalling directly modulates epigenetic complexes required for target gene activation. Thus, in addition to the PRC2 to *Jmjd3* switch, Shh signalling also induces the formation of an epigenetic coactivator complex containing at least *Jmjd3* and Set1/MLL, which regulates target gene activation coordinately by modulating the bivalent domains.

***Jmjd3*^{-/-} mice display Shh-dependent developmental defects.**

As *Jmjd3* is a key factor in Shh-induced epigenetic switch and gene activation, we examined its function in Shh-activation-dependent developmental processes. As shown by analysis of *Gli2*^{-/-} mice, Gli2-mediated Shh activation is required for multiple developmental processes such as hair follicle development, ventral neural tube patterning and cerebellum progenitor proliferation^{8,40–42}. Like *Gli2*^{-/-} mice, *Jmjd3*^{-/-} mice die at birth due to respiratory failure^{24,25,43}. Interestingly, *Jmjd3*^{-/-} mice display multiple defects similar to *Gli2*^{-/-} mice in Shh/Gli2-dependent developmental processes.

As a morphogen, Shh is important for neural tube patterning and neural progenitor specification. During neural tube development, Shh mainly functions to antagonize GliR activity, whereas GliA is only required for the formation of the floor plate and

specification of the most ventral neural progenitors^{6,7}. *Gli2*^{-/-} neural tubes display reduced expression of markers for floor plate and V3 interneuron progenitors^{40,41}. *Jmjd3* is expressed in the ventral neural tube but not in the floor plate⁴⁴. In E10.5 *Jmjd3*^{-/-} neural tubes, V3 interneuron progenitor marker *Nkx2.2* levels were significantly reduced (Supplementary Fig. 12A,A',C,C',F) and Olig2-expressing motor neuron progenitor regions were expanded (Supplementary Fig. 12B,B',C,C',F). These defects are similar to those observed in *Gli2*^{-/-} embryos⁴⁰. We also observed a reduction of FoxA2 expression in *Jmjd3*^{-/-} neural tubes but not in the floor plate (Supplementary Fig. 12D,D'), possibly due to the absence of *Jmjd3* in the floor plate or the usage of alternative activation mechanisms. The enriched expression of *Ptch1* in the most ventral neural tubes was also reduced in *Jmjd3*^{-/-} embryos (Supplementary Fig. 12E,E'). Thus, these results are consistent with a function of *Jmjd3* in GliA-dependent target gene expression and ventral neural tube development.

Shh-dependent Gli2 activation is essential for embryonic hair follicle development. *Gli2*^{-/-} embryos exhibit an arrest in hair follicle development with reduced cell proliferation⁴². When hair follicles in the sections of E18.5 *Jmjd3*^{-/-} skin were analysed, we observed similarly delayed development of hair follicles. Although both control (wild type and *Jmjd3*^{+/-}) and *Jmjd3*^{-/-} skins contain hair follicles from all stages⁴⁵ (stage 1 to 5, Supplementary Fig. 13A–D), *Jmjd3*^{-/-} hair follicles were arrested at earlier developmental stages with a peak at stage 2 (Supplementary Fig. 13E). Control hair follicles grew deeper and had more mature morphologies with a peak at stage 3 (Supplementary Fig. 13E). This defect in Shh/GliA-dependent hair follicle development further corroborates the importance of *Jmjd3* in Shh signalling activation.

***Jmjd3* is required for Shh-dependent CGNP proliferation.**

During cerebellum development from late embryonic to the early postnatal stage (E18.5–P14), CGNPs in the external granule layer (EGL) undergo significant expansion and differentiation into granule neurons, the most abundant neuron type in the nervous system. Multiple signalling pathways and transcription factors coordinate to regulate this process, and Shh-mediated Gli activation is necessary for CGNP proliferation^{9–11}. Interestingly, during the period from E16.5 to P5, there is a global decrease of H3K27me3 and increase of H3K4me3 and H3K27Ac in the cerebellum (Fig. 5a). The decrease of global H3K27me3 levels was apparent in EGL CGNPs (Fig. 5b) and correlated with the expression of a large amount of genes required for rapid expansion and differentiation of CGNPs at P5. Specifically, at Shh target genes, the activation of *Gli1* expression at P5 was accompanied by a decrease of H3K27me3 and an increase of H3K4me3 (Fig. 5c), which is similar to the signalling-induced resolution of the bivalent domain in MEFs. These data suggest that the Shh-induced epigenetic switch also occurs in the developing cerebellum to modulate the bivalent domain and activate target genes, which contributes to the global change of H3K27me3 levels.

Despite the low global level of H3K27me3, EZH2 protein levels remained high in P5 CGNPs (Fig. 5b), suggesting that a high level of H3K27me3 demethylase activity is present. We observed that *Jmjd3* expression was increased during cerebellar development from E16.5 to P4 (Fig. 5d). In P5 cerebellum, *Jmjd3* was enriched in EGL (Fig. 5e). Interestingly, at E18.5, *Jmjd3*^{-/-} mice displayed decreased cerebellum size and lack of foliation (Fig. 5f), which are similar to the defects observed in the *Gli2*^{-/-} cerebellum⁸ and are likely caused by impaired CGNP proliferation. To directly determine the function of *Jmjd3* in




Figure 4 | Coordinated functions of Jmjd3 and Set1/MLL regulate Shh-activated gene transcription. (a) Both the enzymatic and non-enzymatic activities of Jmjd3 are required for its function in Shh-induced gene activation. NIH3T3 cells infected with *Jmjd3* shRNA or vector control were transfected with plasmids co-expressing GFP-Gli1 and indicated Jmjd3 proteins or vector controls. Levels of endogenous *Gli1* and *Ptch1* were determined by RT-qPCR (means \pm s.d., $n = 3$). (b) Expression of HA-tagged Jmjd3 proteins and exogenous GFP-Gli1 levels in transfected cells as detected by western blot. (c) Binding of Jmjd3 and mutants to *Gli1* regulatory region was determined by HA ChIP-qPCR. 'NS' indicates not significant (means \pm s.d., $n = 3$). (d) Set1/MLL complexes are important for Shh-induced target gene activation. RNAi-mediated inhibition of expression of individual Set1/MLL subunits Ash2L, DPY30, RbBP5 and WDR5 significantly impaired *Gli1* expression in the presence of Shh as measured by RT-qPCR (means \pm s.d., $n = 3$). (e) Shh-induced binding of WDR5 to Shh target genes requires the presence of Jmjd3. Shown are ChIP-qPCR analyses with antibodies against endogenous WDR5 and H3K4me3 in NIH3T3 cells expressing shRNA targeting *Jmjd3* or scrambled shRNA in the basal or Shh-treated conditions. *CD4* was the negative control (means \pm s.d., $n = 3$). (f) Shh enhances the interactions between Jmjd3 and Set1/MLL subunits. NIH3T3 cells co-transfected with plasmids expressing FLAG-Jmjd3 and HA-Ash2L were treated with or without Shh. An anti-FLAG antibody was used for immunoprecipitation, and antibodies against FLAG or HA were used for western blot. Significance was determined using *t*-test or ANOVA with *post hoc t*-test; ** indicates $P < 0.01$ and * indicates $P < 0.05$. The comparisons are all against the control samples.

CGNP proliferation, we inactivated Jmjd3 using RNAi in Shh-treated P4 CGNP cultures. Reduction of *Jmjd3* levels in CGNPs significantly impaired the expression of Shh-induced genes such as *Gli1* and mitogenic *Ccnd1* but not other genes such as *Brg1* and the CGNP marker *Math1* (Fig. 5g). The proliferation of CGNPs in which *Jmjd3* expression was inhibited was significantly impaired as shown by the lower BrdU incorporation rates compared with control cultures (Fig. 5h). Although neither Shh treatment nor *Jmjd3* inhibition in CGNPs led to global changes of histone modifications, we observed altered H3K27me3 as well as H3K4me3 and H3K27Ac levels at *Gli1* regulatory

regions in Shh-treated *Jmjd3*-deficient cultures compared with the controls (Fig. 5i-k). A Cre-induced *Jmjd3* conditional deletion⁴⁶ in CGNP cultures displayed similar defects in Shh target gene expression and altered histone modifications (Supplementary Fig. 14). Thus, Jmjd3 regulates Shh-activated gene expression and CGNP proliferation by modulating the chromatin environment.

Inhibition of Jmjd3 impairs medulloblastoma cell growth. Mutations leading to constitutively active Shh signalling cause Shh-subtype medulloblastoma, the progression of which also




Figure 5 | *Jmjd3* is required for Shh-dependent CGNP proliferation. (a) Global changes of modified histone levels during cerebellum development evaluated by western blot. (b) Immunostaining of sections of E16.5 and P5 cerebella with antibodies against modified histones and EZH2. The EGL is the dense cell layer outlining the cerebellum. (c) Local changes of H3K27me3 and H3K4me3 at *Gli1* regulatory region in E16.5 and P5 cerebella (means \pm s.d., $n = 3$). (d) RT-qPCR analysis of *Jmjd3* in NIH3T3 and MEF cells and in cerebellum (CB) and medulloblastoma (MB) samples (means \pm s.d., $n = 3$). (e) In situ hybridization of P5 CB with *Jmjd3* antisense or sense probes. Note the enriched *Jmjd3* expression in EGL. (f) H&E staining of cerebella from E18.5 wild-type and *Jmjd3*^{-/-} mice. The average length of EGL per cerebellum section is shown on the right (means \pm s.d., $n = 4$). (g) Inhibition of *Jmjd3* expression in cultured CGNPs results in defective Shh-induced gene expression as shown by RT-qPCR. (h) *Jmjd3* knockdown in cultured CGNPs decreases proliferation (as shown by BrdU incorporation) (means \pm s.d., $n = 3$). (i) Western blots indicating global histone modification levels in CGNP cultures in the absence and presence of Shh treatment with or without *Jmjd3* shRNA treatment. (j) Immunostaining of sections of E18.5 wild-type and *Jmjd3*^{-/-} cerebella with antibodies against modified histones. (k) Decrease in *Jmjd3* levels in Shh-treated CGNP cultures by lentiviral-expressed shRNA resulted in significant changes of histone modifications at the *Gli1* regulatory region as shown by ChIP-qPCR. Histone H3 ChIP was used for normalization (means \pm s.d., $n = 3$). Significance was determined by Student's *t*-test; ** indicates $P < 0.01$ and * indicates $P < 0.05$.

requires the active signalling pathway^{4,47}. Thus, as a key epigenetic coactivator of Shh target genes, *Jmjd3* might be targeted to inhibit medulloblastoma growth. We used a mouse model with a Cre-inducible *SmoM2* gene (a point mutation in *Smo*) to generate Shh-subtype medulloblastoma⁴⁸ (Fig. 6a).

SmoM2-induced medulloblastoma cells contain much lower H3K27me3 levels than normal cerebellar tissues (Fig. 6b,c). As a significant amount of EZH2 was expressed in *SmoM2*-induced medulloblastoma (Fig. 6b-d), the low H3K27me3 levels suggest that H3K27me3 demethylase is active in these tumour

cells. Notably, although *Jmjd3* is mutated in some cancers and even in non-Shh-type medulloblastoma^{47,49}, it has not been found mutated in Shh-type medulloblastoma in several genome-wide exome-sequencing projects^{47,50–53}, indicating a potential requirement of *Jmjd3* for these tumours.

To determine the function of *Jmjd3* in medulloblastoma, we first confirmed that in SmoM2 medulloblastoma the *Gli1* regulatory regions contain lower H3K27me3 levels and higher H3K4me3 and H3K27Ac levels than normal cerebellum (Fig. 6e). Reducing *Jmjd3* expression using virally expressed shRNA significantly impaired the expression of Shh target genes such as *Gli1*, *Ptch1*, *Ccnd1* and *N-myc* in cultured SmoM2 tumour cells (Fig. 6f). This defect was not due to the differentiation of tumour cells because the tumour progenitor marker *Math1* was not significantly reduced (Fig. 6f). Local H3K27me3 levels on the *Gli1* gene were significantly increased on inhibition of *Jmjd3* expression (Fig. 6g). The impaired Shh target gene expression in *Jmjd3*-deficient tumour cells led to a growth inhibition similar to that observed in *Gli1/2*-deficient tumour cultures as indicated by a cell survival assay (Fig. 6h). Therefore, as *Jmjd3* is required for Shh-subtype medulloblastoma growth, Shh-induced epigenetic switching events may be targeted to inhibit medulloblastoma growth.

Discussion

In this report, we have identified a bivalent chromatin domain tightly associated with the poised states of Shh target genes. We have shown that Shh signalling induces a local epigenetic switch as well as the formation of a *Jmjd3*-centred epigenetic coactivator complex, which functions coordinately with GliA to resolve the bivalent domain and to activate transcription. We have also demonstrated the essential role of *Jmjd3* in regulating Shh-dependent developmental processes and tumour proliferation. The epigenetic mechanisms elucidated here significantly advance our understanding of Shh signalling and provide insights into the mechanisms of Shh-related cancers and diseases.

Activation of Shh signalling induces a local epigenetic switch from PRC2 to *Jmjd3* at Shh target genes to facilitate the resolution of bivalent chromatin domains. The removal of H3K27me3 in response to Shh likely resulted from both the recruitment of *Jmjd3* and the release of PRC2. We propose that, on Shh signalling stimulation, the activation and binding of Gli1/2 mediate the recruitment of *Jmjd3* and subsequently the coactivator complex, which displaces PRC2 at the regulatory regions, resolves bivalent domains and activates target genes (Supplementary Fig. 16). In the absence of *Jmjd3*, GliA binding




Figure 6 | *Jmjd3* is required for Shh-subtype medulloblastoma cell growth. (a) H&E staining of sections of a P90 normal cerebellum and one with a SmoM2-induced MB. (b) Levels of histone modifications and EZH2 in normal cerebellum (CB) and SmoM2-induced medulloblastoma (MB) were analysed by immunostaining. IGL = internal granule layers. (c) Western blots indicating global levels of histone modifications and EZH2 in normal CB and SmoM2 MB. (d) RT-qPCR analysis of *EZH2* in NIH3T3 and MEF cells and in CB and MB samples (means \pm s.d., $n = 3$). (e) ChIP-qPCR analysis of histone modification levels in the *Gli1* regulatory region in MB and normal CB. Histone H3 ChIP was used for ChIP normalization. (means \pm s.d., $n = 3$). (f) Cultured SmoM2 medulloblastoma tumour cells were infected with lentiviruses expressing either *Jmjd3* shRNA or scrambled control. Levels of Shh target genes and medulloblastoma progenitor marker *Math1* were measured with RT-qPCR (means \pm s.d., $n = 3$). (g) The H3K27me3 level in the *Gli1* gene regulatory region was increased after inhibition of *Jmjd3* expression (means \pm s.d., $n = 3$). (h) Cultured SmoM2 tumour cells were infected with viruses expressing control or shRNA targeting *Jmjd3* or *Gli1/2*. The survival rates of cells relative to the control culture were measured using the ATP cell viability assay (means \pm s.d., $n = 3$). Significance was determined by Student's *t*-test or ANOVA with *post hoc t*-test; ** indicates $P < 0.01$ and * indicates $P < 0.05$.

was not affected, but PRC2 release was impaired and Set1/MLL was not recruited. Although *Jmjd3* also functions in other pathways, in tissues that are predominantly dependent on GliA function, such as embryonic hair follicle, ventral neural tube, cerebellum, and Shh-type medulloblastoma, inhibition of *Jmjd3* expression and *Gli2* deletion led to similar phenotypes. Thus, *Jmjd3* plays an essential role in Shh-induced gene activation by coordinating the changes of chromatin environments. Shh signalling also significantly enhances the interactions between *Jmjd3* and Set1/MLL complexes. Although the biochemical bases for this Shh-induced interaction remain unclear, the possibility that Shh signalling directly modifies epigenetic cofactors and regulate their activities is intriguing.

Although the experiments were performed in populations of cells and we could not exclude the possibility that a fraction of the histone marks may exist in separate cells, our data strongly support the coexistence of H3K27me3 and H3K4me3 at the same loci and cooperative regulation of both marks by Shh signalling. The Shh-induced interaction between *Jmjd3* and MLL suggests that they function together to regulate both histone marks. Importantly, loss of *Jmjd3* not only affected the H3K27me3 levels at Gli target genes, but also impaired Shh-induced recruitment of Set1/MLL complexes and increase of H3K4me3 levels (Fig. 4f). In CGNPs, loss of *Jmjd3* also affected the levels of both histone marks at Shh target genes (Fig. 5k). These results could unlikely be explained if the two histone marks are in separate cells and regulated independently.

We propose that Shh-induced transcription factor exchange from GliR to GliA triggers the switch of the associated epigenetic complexes. Previous work and this report demonstrate that a complex epigenetic environment controls Shh target gene expression. It has been shown that Shh signalling also functions as switches for several epigenetic regulators that may coordinate with PRC2/*Jmjd3* to regulate transcription outcomes. We have previously reported that Shh activation enables Brg1-containing BAF chromatin remodelling complexes to switch from a repressor to an activator state, a switch likely mediated by interacting with different Gli transcription factors and other epigenetic regulators¹². Brg1 may either antagonize or facilitate PRC2 function in a context-dependent manner in embryonic stem cell gene expression⁵⁴. Brg1 has also been shown to interact with *Jmjd3* to induce specific target gene expression⁵⁵. Thus, the Brg1 complex may coordinate with these histone modifiers to regulate Shh signalling. Indeed, deletion of *Brg1* resulted in altered histone modifications (ref. 12 and our unpublished data).

In addition, histone deacetylases (HDACs) and histone acetyl transferases (HATs) have been directly or indirectly linked to Shh signalling transcription regulation^{12,56–58}. Interestingly, Shh signalling activities also alter HDAC function. In basal conditions, HDACs are likely involved in repressing the expression of Shh target genes by deacetylating histones¹². However, on signal activation, HDAC1/2 function as activators of Shh target genes possibly by deacetylating and activating *Gli1/2* (refs 12,56). HDACs have been shown to tightly interact with Brg1 as well as PRC2 complexes^{12,59}. Deletion of the gene encoding PRC2 subunit EZH2 led to global increase of H3K27Ac^{35,60} (Supplementary Fig. 15). On Shh stimulation, the resolution of the bivalent domain is also accompanied with an increase of H3K27Ac at the regulatory regions (Supplementary Fig. 2). It is not clear whether the increased H3K27Ac is a byproduct of H3K27me3 loss or due to active recruitment of the H3K27 acetyltransferase p300/CBP^{60,61}. In addition, *Jmjd3* has been shown to interact with proteins involved in transcription elongation⁶², which may also function to regulate Shh signalling.

During development, Shh can function as a mitogen or a morphogen. For the mitogenic function, Shh-induced GliA-

mediated transcription activation is required. In this study, we demonstrated that during cerebellum development, when active Shh signalling plays an essential role in CGNP proliferation, Shh activation is accompanied by a decrease of H3K27me3 and an increase of H3K4me3 levels. Shh-subtype medulloblastomas are characterized by low levels of H3K27me3. We have shown that a key epigenetic factor *Jmjd3* is required for the histone modification changes and Shh target gene activation in CGNPs and medulloblastoma cells. Deletion of *Jmjd3* affects cerebellum growth and CGNP proliferation. Inhibiting enzymatic and/or non-enzymatic activities of *Jmjd3* may effectively inhibit medulloblastoma growth.

In addition to the mitogenic function, Shh also functions as a morphogen to induce dosage-dependent expression of target genes². The diverse outputs of Shh signalling are thought to be determined by the combination of activities of GliA and GliR^{6,7,63}. Thus, the mechanisms that underlie basal versus signalling-induced conditions identified here might also function in more complicated Shh-responsive systems. The morphogenic activities of Shh signalling are largely mediated by antagonizing GliR function^{64,65}. We identified PRC2 as a corepressor of Shh target genes. However, we believe that PRC2 is only part of a complex corepressor network associated with GliR. GliA activities are required in the areas receiving highest Shh signalling. We also showed modest but significant defects in *Jmjd3*^{-/-} neural tubes in the most ventral area. Recent studies have revealed that the dosage-dependent transcription response to Shh results from different affinities for Gli-binding sites, other tissue-specific transcription factors, and functional interactions between different target genes^{6,7,63}. It is likely that chromatin environment and epigenetic regulators also play important roles in determining the transcription outcomes of target genes in response to Shh. Additional genetic tools as well as more sensitive ChIP techniques will be needed to directly analyse the epigenetic regulation of the complex Shh-responsive systems.

In summary, our study revealed a novel epigenetic mechanism that regulates Shh-induced gene activation. We identified *Jmjd3* as a key regulator of Shh-activated gene expression and Shh-dependent developmental processes and tumour growth. In the future, the characterization of the components and analysis of the dynamics of epigenetic complexes downstream of Shh signalling will reveal the mechanisms underlying the diverse transcription activities of the signalling during development and in diseases.

Methods

Mice. *Jmjd3*^{-/-} MEFs were produced from E15.5 *Jmjd3*^{-/-} embryos²⁵. This allele deletes exons 14–21, which encode a region that includes the JmJC demethylase domain. RT-PCR primers *Jmjd3*_koF1 and *Jmjd3*_koR1 (Supplementary Information) were used to detect the deletion of the *Jmjd3* mRNA. E10.5 and E18.5 *Jmjd3*^{-/-} embryos were produced from mice containing a *Jmjd3*/*Kdm6b*^{tm1(KOMP)Wisi} allele (Shpargel and Magnuson, unpublished data). This allele with exons 11–20 replaced by a Neo cassette was targeted by Knockout Mouse Project (KOMP) in JM8 embryonic stem cells of C57BL/6N origin. Embryonic stem cells were injected into C57BL/6J-*Tyr^{c-2l}*/J blastocysts. Following germline transmission, mice were maintained on the C57BL/6J background. Homozygotes were generated by heterozygous intercrosses. Both *Jmjd3* alleles delete a large portion of the protein, and these mice die at birth due to respiratory defects, which is similar to the phenotype of another *Jmjd3* knockout allele²⁴. Both alleles also result in similar skin and cerebellum defects at E18.5 and are likely null alleles. *Jmjd3* conditional knockout allele was generated as previously described with exons 15 to 21 flanked by two LoxP sites⁴⁶. SmoM2 mice⁴⁸ and CAG-CreER⁶⁶ mice were purchased from Jackson Laboratory. The SmoM2 CAG-CreER mice have a high rate of spontaneous medulloblastoma development before 2 months of age (~40%). These mice were maintained on a mixed genetic background at UT Southwestern Medical Center Animal Facility.

Primary MEF, CGNP and medulloblastoma cell cultures. Primary MEFs were cultured from E13.5 to E15.5 embryos as described previously¹². In brief, embryo trunks were dissected, trypsinized, dissociated to single cells and cultured in DMEM

media with 10% fetal bovine serum. Primary CGNP cultures were derived from dissociated P4 mouse cerebella and cultured in DMEM/F12 media containing 25 mM KCl, N₂ and 10% FBS. For Shh stimulation, Shh-conditioned medium produced from Shh-CM 293T cells⁶⁷ was added at a 1:20 dilution to MEF and CGNP cultures. MEF cells were treated with Shh in low-serum media 24 h before harvesting. CGNP cells were treated with Shh in high-serum media for 2–3 days. BrdU was added 2 h before analyses. Tumour cells were derived from dissociated SmoM2 medulloblastoma and cultured in the media containing DMEM/F12, B27, N2, EGF and FGF2.

Plasmid construction, virus preparation and transfection/infection. The shRNA sequences targeting *Jmjd3* (5'-AGCACTCGATGCCTCATTCATA-3' (ref. 21), *Ash2L* (5'-CGAGTCTTGTTAGCCCTACAT-3'), *DPY30* (5'-GCGTTGA GAGAATAGTCGAAA-3'), *RbBP5* (5'-GCTCTATTGTATTACCCATT-3'), *WDR5* (5'-GCCGTTTCATTCAACCGTGAT-3'), *Gli1* (5'-GCTCAGCTGTGTGTAATTAC-3') and *Gli2* (5'-CCAACCAGAACAGCAGAACAA-3') were cloned into the PLKO lentiviral vector. The PLKO construct with a scrambled shRNA sequence was used as a negative control. Lentiviral vector pSin4-EF2-IRES-Puro was used to generate expression constructs for tagged Gli, Jmjd3, Ash2L, WDR5 and EZH2. GliDBD fusion proteins were generated by fusing the Gli3 Zinc-finger domains (aa 477–636) with EZH2, Jmjd3 full-length protein or the C-terminal fragment including JmJC domain (aa 1,141–1,641). Lentiviruses were prepared according to a previously described procedure¹². PolyJet (Signagen) was used for plasmid transfection of cultured cells. Attached cultured cells were infected at a multiplicity of infection (MOI) of 5 for 24 h in media with 8 µg ml⁻¹ polybrene.

RNA-seq. Cultured primary MEFs (second passage) were treated with or without Shh-conditioned media for 24 h before harvesting. Total RNAs were extracted, and RNA-seq libraries were prepared using Illumina RNA-Seq Preparation Kit and sequenced by an HiSeq 2000 sequencer. RNA-seq reads were mapped using TopHat with default settings (<http://tophat.cbcb.umd.edu>). The mapped reads with the Phred quality score <20 were filtered out, whereas the duplicates were marked but not removed using SAMTOOLS⁶⁸ and PICARD (<http://picard.sourceforge.net>). Transcript assembly and transcript abundance quantification were carried out using CUFFLINKS, and then differential expression analysis between Shh-treated and untreated MEFs was performed using CUFFDIFF⁶⁹. The differentially expressed genes with $P < 0.05$ were selected for histone modification analyses (Supplementary Table 1).

Immunoblotting. For immunoblotting, cells or tissues were lysed in RIPA buffer (50 mM Tris, pH 8, 250 mM NaCl, 0.05% SDS, 0.5% DOC, 1% NP-40). Histone fractions were prepared with standard acid extraction (0.2 N HCl). Cell lysates or histone fractions were separated on SDS-PAGE (SDS-polyacrylamide gel electrophoresis) gels. Antibodies used were mouse monoclonal antibodies against Gli1 (#2643, Cell Signalling), HA (HA-7, Sigma), GAPDH (G9545, Sigma), H3K27me3 (#39536, Active Motif), H3H4me3 (ab8580, Abcam), H3K27Ac (ab4729, Abcam), histone H3 (ab1791, Abcam), Myc (9E10, Bishop), EZH2 (612667, BD Biosciences), SUZ12 (#3737, Cell Signalling) and FLAG (F1804, M2, Sigma). HRP-conjugated secondary antibodies were purchased from Jackson Immunology. Uncropped immunoblots are shown in Supplementary Fig. 17.

Immunohistology and *in situ* hybridization. Timed mouse pregnancies were determined by plugging date as day 0.5. Haematoxylin and eosin (H&E) staining and immunostaining were performed on paraffin sections. Antibodies used were against Olig2 (AB9610, Chemicon), NKX2.2 (74.5A5-s, DSHB, University of Iowa), FoxA2 (4C7-s, DSHB, University of Iowa), EZH2 (#3737, BD Bioscience), H3K4me3 (C42D8, Cell Signalling) and H3K27me3 (07-449, Millipore). The images were visualized using an Olympus BX50 microscope. *In situ* hybridization analyses were performed as described previously¹² on cryosections (P5 cerebellum) or paraffin sections (E10.5 neural tubes). The *Ptch1* and *Jmjd3* probes correspond to nucleotides (nts) 850–1,637 and nts 925–1,720 of their cDNAs, respectively.

Co-immunoprecipitation experiments. Antibodies were against the HA-tag (ab9110, rabbit, Abcam) or FLAG-tag (F2426, M2 beads, Sigma). Shh-responsive NIH3T3 cells were transiently transfected with plasmids expressing HA- or FLAG-tagged proteins using PolyJet (Signagen). Mock transfection was used as the negative control. Cells were harvested 24–48 h after transfection and were lysed with co-IP Lysis Buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, with protease inhibitor freshly added). Cell lysates were snap-frozen in liquid nitrogen and then thawed on ice followed by sonication to facilitate cell lysis. After centrifugation, appropriate antibodies were added to pre-cleared cell lysate and incubated at 4 °C overnight. Samples were incubated with protein A beads (GE Healthcare) for 1 h; beads were washed with co-IP buffer four times. Precipitated proteins were eluted by boiling in 2 × Sample Buffer before SDS-PAGE and western blot analysis. For λ -phosphatase treatment, 400 U of enzyme (Sigma) was added to cell lysates followed by 30 min incubation at 37 °C.

Chromatin immunoprecipitation. ChIP experiments were performed as described previously¹². Dissociated cells were crosslinked with PFA or double crosslinked with DSG (Pierce) and PFA, and sonicated to fragments (200–1,000 bp). Antibodies used were against H3K27me3 (07-449, Millipore), H3K4me3 (ab8580, Abcam), H3K27Ac (ab4729, Abcam), histone H3 (ab1791, Abcam), SUZ12 (#3737, Cell Signalling), EZH2 (612667, BD Bioscience), Jmjd3 (ab85392, Abcam)⁷⁰, WDR5 (A302-429A, Bethyl Laboratories), HA (ab9110, Abcam) and FLAG (F1804, M2, Sigma). Rabbit IgG was used as a negative control. Precipitated DNA was purified and subjected to real-time PCR.

RT-PCR and q-PCR. RNAs from cells or tissues were extracted with TRIZOL (Invitrogen) or the RNeasy kit (Qiagen). cDNAs were synthesized by reverse transcription using Superscript III (Invitrogen), followed by PCR or quantitative PCR analysis. An ABI-7500 real-time PCR system was used for quantitative PCR. Levels of *GAPDH* mRNA were used to normalize input RNA. Graphics shown are representative of experiments performed in triplicate. Experiments were repeated for at least three times. Standard errors were calculated according to a previously described method¹². The primer sequences are listed in the Supplementary Information.

Statistical analysis. Data are expressed as means \pm s.d. Statistical analysis was performed by either analysis of variance with ANOVA *post hoc t*-test for multiple comparisons or a two-tailed unpaired Student's *t*-test. A *P* value of <0.05 was considered significant.

References

- Jiang, J. & Hui, C. C. Hedgehog signaling in development and cancer. *Dev. Cell* **15**, 801–812 (2008).
- Fuccillo, M., Joyner, A. L. & Fishell, G. Morphogen to mitogen: the multiple roles of hedgehog signalling in vertebrate neural development. *Nat. Rev. Neurosci.* **7**, 772–783 (2006).
- Ingham, P. W., Nakano, Y. & Seger, C. Mechanisms and functions of Hedgehog signalling across the metazoa. *Nat. Rev. Genet.* **12**, 393–406 (2011).
- Barakat, M. T., Humke, E. W. & Scott, M. P. Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. *Trends Mol. Med.* **16**, 337–348 (2010).
- Gilbertson, R. J. & Ellison, D. W. The origins of medulloblastoma subtypes. *Annu. Rev. Pathol.* **3**, 341–365 (2008).
- Oosterveen, T. *et al.* Mechanistic differences in the transcriptional interpretation of local and long-range shh morphogen signaling. *Dev. Cell* **23**, 1006–1019 (2012).
- Peterson, K. A. *et al.* Neural-specific Sox2 input and differential Gli-binding affinity provide context and positional information in Shh-directed neural patterning. *Genes Dev.* **26**, 2802–2816 (2012).
- Corrales, J. D., Rocco, G. L., Blaess, S., Guo, Q. & Joyner, A. L. Spatial pattern of sonic hedgehog signaling through Gli genes during cerebellum development. *Development* **131**, 5581–5590 (2004).
- Dahmane, N. & Ruiz i Altaba, A. Sonic hedgehog regulates the growth and patterning of the cerebellum. *Development* **126**, 3089–3100 (1999).
- Wallace, V. A. Purkinje-cell-derived Sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum. *Curr. Biol.* **9**, 445–448 (1999).
- Wechsler-Reya, R. J. & Scott, M. P. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. *Neuron* **22**, 103–114 (1999).
- Zhan, X., Shi, X., Zhang, Z., Chen, Y. & Wu, J. I. Dual role of Brg chromatin remodeling factor in Sonic hedgehog signaling during neural development. *Proc. Natl Acad. Sci. USA* **108**, 12758–12763 (2011).
- Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. *Nature* **469**, 343–349 (2011).
- Bernstein, B. E. *et al.* A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell* **125**, 315–326 (2006).
- Mills, A. A. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. *Nat. Rev. Cancer* **10**, 669–682 (2010).
- Voigt, P., Tee, W. W. & Reinberg, D. A double take on bivalent promoters. *Genes Dev.* **27**, 1318–1338 (2013).
- Cao, R. *et al.* Role of histone H3 lysine 27 methylation in Polycomb-group silencing. *Science* **298**, 1039–1043 (2002).
- Agger, K. *et al.* UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. *Nature* **449**, 731–734 (2007).
- Lan, F. *et al.* A histone H3 lysine 27 demethylase regulates animal posterior development. *Nature* **449**, 689–694 (2007).
- Lee, M. G. *et al.* Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. *Science* **318**, 447–450 (2007).
- De Santa, F. *et al.* The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. *Cell* **130**, 1083–1094 (2007).

22. Hong, S. *et al.* Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. *Proc. Natl Acad. Sci. USA* **104**, 18439–18444 (2007).
23. Cho, Y. W. *et al.* PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. *J. Biol. Chem.* **282**, 20395–20406 (2007).
24. Burgold, T. *et al.* The H3K27 demethylase JMJD3 is required for maintenance of the embryonic respiratory neuronal network, neonatal breathing, and survival. *Cell Rep.* **2**, 1244–1258 (2012).
25. Satoh, T. *et al.* The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. *Nat. Immunol.* **11**, 936–944 (2010).
26. Shpargel, K. B., Sengoku, T., Yokoyama, S. & Magnuson, T. UTX and UTY demonstrate histone demethylase-independent function in mouse embryonic development. *PLoS. Genet.* **8**, e1002964 (2012).
27. Wang, C. *et al.* UTX regulates mesoderm differentiation of embryonic stem cells independent of H3K27 demethylase activity. *Proc. Natl Acad. Sci. USA* **109**, 15324–15329 (2012).
28. Bilodeau, S., Kagey, M. H., Frampton, G. M., Rahl, P. B. & Young, R. A. SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state. *Genes Dev.* **23**, 2484–2489 (2009).
29. Taipale, J. *et al.* Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. *Nature* **406**, 1005–1009 (2000).
30. Lee, E. Y. *et al.* Hedgehog pathway-regulated gene networks in cerebellum development and tumorigenesis. *Proc. Natl Acad. Sci. USA* **107**, 9736–9741 (2010).
31. Vokes, S. A., Ji, H., Wong, W. H. & McMahon, A. P. A genome-scale analysis of the cis-regulatory circuitry underlying sonic hedgehog-mediated patterning of the mammalian limb. *Genes Dev.* **22**, 2651–2663 (2008).
32. Kallin, E. M. *et al.* Genome-wide uH2A localization analysis highlights Bmi1-dependent deposition of the mark at repressed genes. *PLoS Genet.* **5**, e1000506 (2009).
33. Mikkelsen, T. S. *et al.* Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature* **448**, 553–560 (2007).
34. Su, I. H. *et al.* Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. *Nat. Immunol.* **4**, 124–131 (2003).
35. Wang, L., Jin, Q., Lee, J. E., Su, I. H. & Ge, K. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. *Proc. Natl Acad. Sci. USA* **107**, 7317–7322 (2010).
36. Wyngaarden, L. A., Delgado-Olguin, P., Su, I. H., Bruneau, B. G. & Hoppyan, S. Ezh2 regulates anteroposterior axis specification and proximodistal axis elongation in the developing limb. *Development* **138**, 3759–3767 (2011).
37. Di Meglio, T. *et al.* Ezh2 orchestrates topographic migration and connectivity of mouse precerebellar neurons. *Science* **339**, 204–207 (2013).
38. Pavletich, N. P. & Pabo, C. O. Crystal structure of a five-finger GLI-DNA complex: new perspectives on zinc fingers. *Science* **261**, 1701–1707 (1993).
39. Smith, E., Lin, C. & Shilatifard, A. The super elongation complex (SEC) and MLL in development and disease. *Genes Dev.* **25**, 661–672 (2011).
40. Ding, Q. *et al.* Diminished Sonic hedgehog signaling and lack of floor plate differentiation in Gli2 mutant mice. *Development* **125**, 2533–2543 (1998).
41. Lei, Q., Zelman, A. K., Kuang, E., Li, S. & Matise, M. P. Transduction of graded Hedgehog signaling by a combination of Gli2 and Gli3 activator functions in the developing spinal cord. *Development* **131**, 3593–3604 (2004).
42. Mill, P. *et al.* Sonic hedgehog-dependent activation of Gli2 is essential for embryonic hair follicle development. *Genes Dev.* **17**, 282–294 (2003).
43. De Santa, F. *et al.* Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. *EMBO J.* **28**, 3341–3352 (2009).
44. Estarás, C. *et al.* Genome-wide analysis reveals that Smad3 and JMJD3 HDM co-activate the neural developmental program. *Development* **139**, 2681–2691 (2012).
45. Paus, R. *et al.* A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. *J. Invest. Dermatol.* **113**, 523–532 (1999).
46. Zhao, W. *et al.* Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. *Cell* **152**, 1037–1050 (2013).
47. Parsons, D. W. *et al.* The genetic landscape of the childhood cancer medulloblastoma. *Science* **331**, 435–439 (2011).
48. Mao, J. *et al.* A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. *Cancer Res.* **66**, 10171–10178 (2006).
49. Berger, M. F. *et al.* Melanoma genome sequencing reveals frequent PREX2 mutations. *Nature* **485**, 502–506 (2012).
50. Robinson, G. *et al.* Novel mutations target distinct subgroups of medulloblastoma. *Nature* **488**, 43–48 (2012).
51. Jones, D. T. *et al.* Dissecting the genomic complexity underlying medulloblastoma. *Nature* **488**, 100–105 (2012).
52. Northcott, P. A. *et al.* Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature* **488**, 49–56 (2012).
53. Pugh, T. J. *et al.* Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature* **488**, 106–110 (2012).
54. Ho, L. *et al.* esBAF facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by regulating polycomb function. *Nat. Cell Biol.* **13**, 903–913 (2011).
55. Miller, S. A., Mohn, S. E. & Weinmann, A. S. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. *Mol. Cell* **40**, 594–605 (2010).
56. Canettieri, G. *et al.* Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. *Nat. Cell Biol.* **12**, 132–142 (2010).
57. Dai, P. *et al.* Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3. *J. Biol. Chem.* **274**, 8143–8152 (1999).
58. Malatesta, M. *et al.* Histone acetyltransferase PCAF is required for Hedgehog-Gli-dependent transcription and cancer cell proliferation. *Cancer Res.* **73**, 6323–6333 (2013).
59. van der Vlag, J. & Otte, A. P. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. *Nat. Genet.* **23**, 474–478 (1999).
60. Pasini, D. *et al.* Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. *Nucleic Acids Res.* **38**, 4958–4969 (2010).
61. Jin, Q. *et al.* Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. *EMBO J.* **30**, 249–262 (2011).
62. Chen, S. *et al.* The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. *Genes Dev.* **26**, 1364–1375 (2012).
63. Balaskas, N. *et al.* Gene regulatory logic for reading the Sonic Hedgehog signaling gradient in the vertebrate neural tube. *Cell* **148**, 273–284 (2012).
64. Rallu, M. *et al.* Dorsoventral patterning is established in the telencephalon of mutants lacking both Gli3 and Hedgehog signaling. *Development* **129**, 4963–4974 (2002).
65. Wijgerde, M., McMahon, J. A., Rule, M. & McMahon, A. P. A direct requirement for Hedgehog signaling for normal specification of all ventral progenitor domains in the presumptive mammalian spinal cord. *Genes Dev.* **16**, 2849–2864 (2002).
66. Hayashi, S. & McMahon, A. P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. *Dev. Biol.* **244**, 305–318 (2002).
67. Chen, J. K., Taipale, J., Young, K. E., Maiti, T. & Beachy, P. A. Small molecule modulation of Smoothened activity. *Proc. Natl Acad. Sci. USA* **99**, 14071–14076 (2002).
68. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
69. Trapnell, C. *et al.* Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat. Biotechnol.* **28**, 511–515 (2010).
70. Sen, G. L., Webster, D. E., Barragan, D. I., Chang, H. Y. & Khavari, P. A. Control of differentiation in a self-renewing mammalian tissue by the histone demethylase JMJD3. *Genes Dev.* **22**, 1865–1870 (2008).

Acknowledgements

We thank Qiu Wang and Yu Chen for technical support, Dr Chao Xing for RNA-seq analyses and Dr Jin Jiang for reagents and critical discussion. This work was supported by grants from March of Dimes Foundation (J.W.), American Cancer Society (J.W.), NIH (R21MH102820, J.W.) and Department of Defense Visionary postdoc fellowship (X.S.).

Author contributions

J.W., X.S. and Z.Z. designed the experiments. X.S., Z.Z., X.Z., M.C. and J.W. performed the experiments, collected the data and analysed the results. T.S., S.A., K.S., T.M., Q.L., R.W., C.W. and K.G. provided critical reagents. J.W. wrote the paper with help from all authors.

Additional information

Accession codes. NCBI SRA SRP047495 for RNA-seq analyses of Shh-responsive genes in MEF cells.

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://www.nature.com/reprintsandpermissions/>

How to cite this article: Shi, X. *et al.* An Epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth. *Nat. Commun.* 5:5425 doi: 10.1038/ncomms6425 (2014).